Amivantamab
Sign in to saveAmivantamab, sold under the brand name Rybrevant, is a bispecific monoclonal antibody used to treat non-small cell lung cancer. Amivantamab is a bispecific epidermal growth factor (EGF) receptor-directed and MET receptor-directed antibody. It is the first treatment for adults with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
Medication
- Generic name
- Amivantamab-Vmjw
- Brand names
- Rybrevant
- Route
- Intravenous
- Type
- Human Prescription Drug
- Manufacturer
- Janssen Biotech, Inc.
Indications: 1 INDICATIONS AND USAGE RYBREVANT is a bispecific EGF receptor-directed and MET receptor-directed antibody indicated: in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor r… (per FDA label)
Clinical Trials
46 registered- PHASE1/PHASE2ACTIVE_NOT_RECRUITINGPhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung CancerM.D. Anderson Cancer Center · NCT06083857
- PHASE2NOT_YET_RECRUITINGCollaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study)Yonsei University · NCT07507188
- PHASE2ACTIVE_NOT_RECRUITINGAmivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKIETOP IBCSG Partners Foundation · NCT05601973
- PHASE2ACTIVE_NOT_RECRUITINGPremedication to Reduce Amivantamab Associated Infusion Related ReactionsJanssen Research & Development, LLC · NCT05663866
- PHASE2ACTIVE_NOT_RECRUITINGEnhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus LazertinibJanssen Research & Development, LLC · NCT06120140
- PHASE1RECRUITINGORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLCORIC Pharmaceuticals · NCT06816992
Article · Deutsch
Amivantamab ist ein monoklonaler Antikörper, der als Arzneistoff zur Behandlung bestimmter Formen des nicht-kleinzelligen Lungenkrebses (NSCLC) eingesetzt wird. Für dieses Anwendungsgebiet erhielt er in den USA im Mai 2021, in der EU im Dezember 2021, unter dem Namen Rybrevant (Janssen Biotech) die Zulassung.
Abstract from DBpedia / Wikipedia · CC BY-SA